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Failure of Dexamethasone to Prevent Polymorphonuclear Leukocyte Infiltration
During Experimental Acute Exudative Pyelonephritis and to
Reduce Subsequent Chronic Scarring
Pascal R. Meylan and Michel P. Glauser From the Division of Infectious Diseases, Department of
Internal Medicine, Centre Hospitalier Universitaire Vaudois,
Lausanne, Switzerland
In experimental acute exudative pyelonephritis (AEP), a role for polymorphonuclear leu-
kocyte (PMNL) infiltration in the pathogenesis of kidney scarring has been suggested
indirectly. To directly quantitate PMNL infiltration during AEP, we developed an assay
for measuring the content in the kidney of myeloperoxidase (MPO), an enzyme present
in PMNLs and absent in kidney tissue. This assay was a specific and sensitive marker
of the kidney PMNL content. We used this assay to measure in rats with AEP the effect
of dexamethasone, administered in an attempt to mitigate the acute inflammatory re-
sponse. Compared with saline, dexamethasone given during AEP strikingly reduced kid-
ney swelling, measured by the kidney-weightincrease, but failed to reduce PMNL infiltra-
tion, measured by the kidney MPO content. Despite reduced kidney swellingduring AEP,
dexamethasone treatment failed to prevent subsequent kidney scarring, an observation
indicating that PMNLs playa role in the development of permanent kidney damage dur-
ing AEP.
We have used a rat model of ascending unilateral ob-
structive pyelonephritis to investigate the relation-
ship among the presence of bacteria in the kidney
parenchyma (infection), the inflammatory processes
that occur in response to infection, and the ensuing
permanent kidney damage. In this model, acute ex-
udative pyelonephyritis (AEP) leads to chronic py-
elonephritis (CPN) with scarring and loss of kidney
parenchyma [1-3]. We [4] and others [5-7] have pre-
viously shown that kidney scars might be prevented
if the acute exudative processes were suppressed by
early antibiotic therapy. In addition, drug-induced
neutropenia aimed at reducing the PMNL infiltra-
tion during AEP afforded protection against CPN
scars despite higher bacterial counts during acute in-
fection [8, 9]. These results were interpreted as in-
direct evidence that renal scarring (CPN) resulted
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from tissue damage due to excessive infiltration of
PMNLs.
Because the acute inflammatory response appears
to playa pivotal role in the pathogenesis of CPN,
we tested the effect of dexamethasone administered
during AEP on the PMNL infiltration (as measured
by the myeloperoxidase [MPO] content of the kid-
neys) and on subsequent kidney scarring.
Materials and Methods
Preparation ofrat exudate PMNLs. For prepar-
ing solubilized MPO, exudation of peritoneal
PMNLs was elicited in rats as described by Baron
and Proctor [10].
Extraction and assay of MPO. MPO was ex-
tracted and assayed as described by Bradley et al.
[11], except that samples were first diluted 1:10in ly-
sis buffer.
Experimental design ofdexamethasone therapy.
Rats received four ip doses of either 1 mL of 0.90/0
NaCI or 1 mL of 0.9% NaCI containing 0.5 mg of
dexamethasone sodium phosphate (Oradexons; Or-
ganon, Oss, the Netherlands), corresponding to 1.75
mg/kg of dexamethasone. Injections were admini-
stered once a day at 8 A.M. over a four-day period.
On the afternoon after the first injection, 230 rats
were operated on in groups of 35-40 with AEP pro-
duced as previously described by using 06:K5:Hl [1,
Dexamethasone and PMNL Exudation
4]. Rats from each treatment group were randomly
selected for killing at 1, 2, 3, 7, or 60 d after opera-
tion. Results of separate experiments werereproduc-
ible and werethus pooled for statistical analysis. Nine
rats died during anesthesia; all surviving rats were
included in the results.
Killing of animals and evaluation of effect of
dexamethasone treatment. Rats were killed as de-
scribed previously [4, 12]. In each experiment the
following parameters were evaluated: (1) The inci-
dence of macroscopic pyelonephritis was tabulated.
Kidneys that do not exhibit pyelonephritic lesions
have been shown to harbor only low bacterial counts
during the first few days after operation; these find-
ings and can be considered to indicate failure to in-
duce pyelonephritis [4, 12]. (2) Bacterial counts were
enumerated in kidney parenchyma (log cfu/g of kid-
ney tissue). (3) The intensity ofthe acute inflamma-
tory changes in the animals killed during AEP was
assessed by the left/right kidney weight ratio (which
provides a quantitative index of the severity of py-
elonephritis and increases in proportion to suppu-
ration during AEP), and the kidney MPO content
(which is calculated from the MPO activity in the
kidney homogenates and takes into account the di-
lution due to homogenization and to the kidney
weight). This parameter was used for estimating the
intensity of PMNL infiltration. (4) The severity of
kidney scarring in animals killed two months after
operation was determined. During CPN the
left/right kidney weight ratio decreases due both to
destruction of the left kidney tissue and to compen-
satory hypertrophy of the right kidney [3].
As well as assessing the left/right kidney weight
ratio as a measure of kidney destruction during CPN,
we took advantage of the quantitative binding of
technetium-99 dimercaptosuccinic acid to cortical
tubular cells [13] to measure the remaining functional
renal parenchyma. Six hours after iv injection of 125
IlCi of technetium-99 dimercaptosuccinic acid, rats
with CPN were killed, and a 1-mL sample of blood
was drawn. The kidneys were excised and weighed,
and radioactivity was counted by solid scintillation.
The amount of circulating label in blood was negligi-
ble compared with that bound to kidneys. Thus, in
addition to the left/right kidney weight ratio, a simi-
lar left/right kidney cpm ratio was computed.
Dexamethasone serum levels. Dexamethasone
levels were determined in sera from five rats after
ip injection of 0.5 mg of dexamethasone sodium
phosphate. Dexamethasone was assayed by high-
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performance liquid chromatography according to the
method described by Lambert et al. [14].
Statistical analysis. Comparisons were done by
the Wilcoxon rank-sum test. Relations between
parameters were analyzed by the linear regression
method. The incidence of pyelonephritis was com-
pared by the 'I} test with Yates'scorrection. Statisti-
cal significance was defined as P< .05. All tests were
two tailed.
Results
Activity ofMPO and effect ofnormal kidney ho-
mogenate on the MPO assay. Normal kidneys con-
tained very low levelsof peroxidase activity. Further-
more, no peroxidase activity was detected in cultures
(evenwhen sonicated) ofEscherichiacoli 06:K5:H1.
The MPa activity recovered from peritoneal
PMNL suspensions in 0.9070 NaCI (1Q6-1OS cells/mL)
was proportional to the number of PMNLs in each
sample (r = . 995): 106 PMNLs yielded 1.98 ± 0.05
(mean ± SE) U of MPa activity.
In testing whether normal kidney homogenate
would interfere with the extraction or assay of MPa,
samples of PMNL suspensions werecentrifuged and
resuspended in either 100 ul, of 0.9% NaCI or 100
ul, of pooled normal kidney homogenate contain-
ing a background level of 0.38 U of peroxidase ac-
tivity/mL of kidney homogenate. Normal kidney ho-
mogenate did interfere to some extent with the MPa
assay: The MPO activity recovered from peritoneal
PMNL aliquots mixed with normal kidney homog-
enate represented only 58.8% ± 3.3% (mean ± SE)
of that recoveredfrom peritoneal PMNLs suspended
in 0.9% NaCl. However, the MPa activity recov-
ered from 106-108 PMNLs/mL suspended in normal
kidney homogenate was proportional to the num-
ber of PMNLs in the specimen (r = .992): 106
PMNLs yielded 1.11 ± 0.04(mean ± SE) U of MPa
activity.
Enzymatic properties of MPO from purified
PMNLs and from pyelonephritic kidney homog-
enates. In contrast to the low level of peroxidase
found in normal kidney homogenates, the peroxidase
activity measured in homogenates of pyelonephritic
kidneys during AEP increased considerably (up to
130 U/mL of kidney homogenate). The sensitivity
to pH changes, heat, azide, and cyanide of this kid-
ney peroxidase activity was similar to that of MPa
from PMNLs harvested from peritoneal exudates
(data not shown).
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Relation between kidney weight increaseand kid-
ney MPO content during AEP. A strong positive
correlation existed between the MPO content and
the left kidney-weight enlargement, expressed by the
left/right kidney weight ratio (r = .82), among 25
pyelonephritic rats killed three days after inoculation.
Correlation between morphological and radioiso-
topic assessment ofkidney parenchymal loss (CPN
scars). The relation between kidney parenchymal
destruction and the reduced kidney weight ratio two
months after operation was assessed in experiments
using technetium-99 dimercaptosuccinic acid. Nine-
teen animals with pyelonephritis of varying severity
demonstrated decreased radioactivity binding in the
left kidney and corresponding increased binding in
the right kidney, a finding showing that the compen-
satory hypertrophy of the right kidney was propor-
tional to the destruction of the left kidney paren-
chyma. There was a very close linear relationship
between the left/right kidney cpm ratio and the
left/right kidney weight ratio: left/right kidney cpm
ratio = [1.04 x (left/right kidney weight ratio)] -
0.12 (r = .985; cpm ratio range, 0.20-0.99). These
observations demonstrated therefore that the left/
right kidney weight ratio represents an accurate mea-
sure of the residual functional mass of the renal pa-
renchyma during chronic scarring.
Effect ofdexamethasone on bacterial counts and
weight increase ofthe left kidney duringAEP. Dexa-
methasone treatment had no significant effect on
bacterial counts in the left kidney at any time at
which animals were killed, in both animals with high
bacterial counts that developed AEP and animals
with low bacterial counts that did not exhibit py-
elonephritic lesions (figure 1). Because exudative le-
sions developed only in animals with high bacterial
counts in the left kidney, the effect of dexametha-
sone on the left/right kidney weight ratio was stud-
ied in this group of animals only. Compared with
saline, dexamethasone treatment reduced by 56070 the
median increase in the left/right kidney weight ra-
tio in animals killed at three days after bladder in-
oculation, the time of peak acute inflammatory re-
sponse (P < .001; figure 2). This effect disappeared
in animals killed later during the course of AEP.
Effect ofdexamethasone on MPO content ofthe
left kidney. Figure 3 shows the MPO content of
the left kidney of animals killed from one to seven
days after operation. Rats with low bacterial counts
in the left kidney and no macroscopic evidence of
AEP had a MPO content of the left kidney similar
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Figure 1. Effect of dexamethasone (squares) vs. control
(circles) treatment on bacterial counts in the left kidney.
The hatched area represents the counts below the thresh-
old of bacterial detection. Data are median values; bars
indicate ranges for each group. The number of animals
in each group is given. Solid symbols represent animals
with macroscopic evidenceof pyelonephritis, these animals
invariablyhad high bacterial counts in the left kidney;open
symbols represent animals with low bacterial counts and
without macroscopic evidence of pyelonephritis.
to that of normal kidneys throughout these inter-
vals. Dexamethasone treatment did not influence the
MPO content in these animals. In rats with high bac-
terial counts in the left kidney and macroscopic signs
of AEP, dexamethasone treatment slightly but sig-
nificantly reduced the MPO content of the left kid-
ney in those rats killed early during the course of
AEP, i.e., at 24 h (P = .04). However, no such differ-
ence was seen at later intervals, when the full devel-
opment of the exudative response occurred and the
MPO content increased considerably.
Effect of dexamethasone on severity of chronic
pyelonephritis. Dexamethasone-treated animals
killed two months after bladder inoculation had
left/right kidney weight ratios similar to those of con-
trols (figure 2). Thus despite the difference in the
left/right kidney weight ratio in dexamethasone-
treated and control animals during AEP, the extent
of parenchymal loss two months later, measured by
kidney weight changes, was similar in both treatment
groups.
Dexamethasone serum level. Two hours after ip
injection of 2.5 mg of dexamethasone phosphate/kg,
the mean ± SD serum level of dexamethasone in
five rats was 556 ± 231 ng/mL; values decreased to
119 ± 60 ng/mL at 6 h and to 22 ± 11lJg/mL at 12h.
Discussion
Several lines of evidence in the present experiments
support the view that the MPO content of kidney
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Figure 2. Effect of dexamethasone (.) vs. control (.)
treatment on kidney swelling during AEP and on severity
of scars during CPN, as reflected by the left/right (L/R)
kidney weight ratio. Data are median values; bars indi-
cate ranges for each group. The number of animals in each
group is given. The star denotes a highly significant 56%
reduction (P < .001)of the left/right ratio in dexametha-
sone-treated animals compared with controls killed three
days after operation. Groups of animals that did not de-
velop pyelonephritis are not shown here. Their left/right
kidney weight ratio increased to 1.4when they were killed
24 h after operation and decreased toward 1.0 in animals
killed later.
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Figure 3. Effect of dexamethasone (squares) vs, control
(circles) treatment on PMNL exudation, measured by the
kidney MPO content. Data are median values; bars indi-
cate ranges for each group. The number of animals in each
group is given. Solid symbols represent animals with mac-
roscopic evidence of pyelonephritis, these animals invari-
ably had high bacterial counts in the left kidney; open sym-
bols represent animals with low bacterial counts and
without macroscopic evidence of pyelonephritis. The x
symbol denotes a slight but significant reduction (P =
.04)of the kidney MPO content in dexamethasone-treated
rats killed one day after inoculation compared with con-
trols. There was no such difference at any later interval.
homogenates can be used for quantitating the
PMNL infiltration in kidney tissue. (1) Isolated rat
PMNLs contained a large amount ofMPO, whereas
normal kidneyhomogenate did not. (2)Despite some
interference of kidney homogenate with the MPO
assay, the measure of the MPO activity was a quan-
titative measure of the number of PMNLs added to
normal kidney homogenate samples. (3) The perox-
idase activity in kidney homogenates increased in
parallel with the macroscopic appearance of sup-
purative foci and the microscopic infiltration with
PMNLs. (4) The peroxidase activity from pye-
lonephritic kidneys had enzymatic properties simi-
lar to the MPO activity extracted from purified
PMNLs. Thus the kidney MPO content could be
used as an index for tissue infiltration by PMNLs,
which would allow the study of the effect of ther-
apeutic interventions on the PMNL component of
the inflammatory response.
The present data show that dexamethasone strik-
ingly reduced the weight increase of the left kidney
at the time of peak acute inflammatory response,
that is, three days after operation. That dexametha-
sone had no significant effect on kidney weight at
the earlier times of killing (one and two days after
operation) is not surprising because the weight in-
crease of the left kidney at this time is partly due
to intrarenal hydronephrosis secondary to left ure-
teralligation [4, 12]. In contrast to its effect on the
weight increase of the left kidney, dexamethasone
failed to reduce the kidney infiltration by PMNLs,
a finding suggesting that dexamethasone acted on
the kidney weight by reducing the plasma exudation,
not cellular migration into kidney tissue. This fail-
ure to reduce PMNL infiltration during AEP was
accompanied two months after operation by a fail-
ure to prevent kidney scarring.
The lack of effect of dexamethasone on PMNL
infiltration was not due to an inadequate dosage, be-
cause the peak serum levelsof dexamethasone in the
rats were five to 10times higher than those achieved
in humans after standard therapeutic doses of 0.1
mg/kg [15-17]. Furthermore, the schedule of ad-
ministration (once a day) seemed appropriate be-
cause dexamethasone was still detectable in serum
12h after injection and because the half-life of the
biologic effects of dexamethasone has been shown
to be about twice that of the serum levels [17]. In-
deed, the dexamethasone treatment schedule used
here led to a potent glucocorticoid effect in the rats,
as demonstrated by both the shrinkage of the spleen
observed in dexamethasone-treated rats (data not
shown), a typical glucocorticosteroid effect due to
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lymphocytic depletion [18],and the reduction of the
weight increase of the left kidney during AEP.
Studies investigating the effects of pharmacolog-
ical doses of glucocorticosteroids on the in vivo
PMNL migration have led to conflicting results in
several experimental systems and demonstrate either
a slight reduction or no effect at all [19-26]. These
apparently conflicting observations may result from
differences with respect to the properties of each an-
imal model used in testing the inflammatory re-
sponse, to the characteristics and dosages of the
glucocorticosteroid used, and to the schedule of ad-
ministration. This latter point might be particularly
relevant because the onset of the hormonal effect
of corticosteroid treatment is usually delayedfor sev-
eral hours [15]. Our experiments differ in three re-
spects from most of the observationsmentionedabove.
(1) PMNL migration occurred in our experiments
in response to the rapid development of high bacte-
rial counts rather than in response to chemical or
immunologic stimuli. (2) The PMNL infiltrates ac-
cumulating in the kidney parenchyma were quanti-
fied over several days, in contrast to observation
periods of no more than 24 h in all of the above-men-
tioned studies. In our experiments, a reduction of
PMNL migrationbydexamethasonewasalsoobserved
very early (24 h) during the development of AEP,
but this effect vanished with the increasing inflam-
matory response, an observation raising questions
about the biologic significance of this early reduc-
tion of PMNL infiltration. (3) Our model allowed
accurate assessment of the permanent deleterious ef-
fect of PMNL infiltration on the kidney parenchyma.
Here dexamethasone failed to reduce PMNL infiltra-
tion during AEP, and the subsequent development
of kidney scars was not prevented. This result sug-
gests that dexamethasone also failed to prevent the
release of cytotoxic inflammatory mediators by stim-
ulated PMNLs [27]. Becausewehavepreviously shown
that PMNLs play an important role in the control
of bacterial multiplication during AEP [8], the pres-
ent observation that dexamethasone treatment did
not influence bacterial counts is additional indirect
evidence that dexamethasone did not reduce the ac-
tivation and bactericidaleffect of PMNLs on ingested
E. coli and confirms that PMNLs are relatively re-
fractory to glucocorticosteroid treatment [28].
In conclusion, weshowed that measurement of the
MPO activity in kidney homogenates can be used
for estimating the PMNL infiltration of the kidney
parenchyma. When administered during AEP, dexa-
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methasone only reduced the swelling of the pyelo-
nephritic kidneys, not the PMNL infiltration. There-
fore the anti-inflammatory effect of dexamethasone
may not necessarily be linked to a reduced migra-
tion of phagocytes toward the inflammatory site, in
contrast to a widely held belief [28]. Furthermore,
dexamethasone failed to protect the rats from py-
elonephritic scarring, a finding suggesting that dexa-
methasone was not able to reduce the cytotoxic ac-
tivity of stimulated PMNLs. These data suggest that
even a striking effect of glucocorticosteroids on the
classic signs of inflammation (i,e., tumor, in the pres-
ent study) is not necessarily linked to reduced tissue
damage (functio laesa).
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